PT2707391T - Anticorpos contra her3 - Google Patents

Anticorpos contra her3

Info

Publication number
PT2707391T
PT2707391T PT127197630T PT12719763T PT2707391T PT 2707391 T PT2707391 T PT 2707391T PT 127197630 T PT127197630 T PT 127197630T PT 12719763 T PT12719763 T PT 12719763T PT 2707391 T PT2707391 T PT 2707391T
Authority
PT
Portugal
Prior art keywords
antibodies against
against her3
her3
antibodies
Prior art date
Application number
PT127197630T
Other languages
English (en)
Inventor
Kharrat Abdelhakim
Dubreuil Olivier
Lazrek Yassamine
Mondon Philippe
Bouayadi Khalil
Chardes Thierry
Pelegrin André
Larbouret Christel
A Gaborit Nadège
Original Assignee
Inserm Institut National De La Santa© Et De La Rech Ma©Dicale
Gamamabs Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inserm Institut National De La Santa© Et De La Rech Ma©Dicale, Gamamabs Pharma filed Critical Inserm Institut National De La Santa© Et De La Rech Ma©Dicale
Publication of PT2707391T publication Critical patent/PT2707391T/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
PT127197630T 2011-05-13 2012-05-11 Anticorpos contra her3 PT2707391T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11305583 2011-05-13

Publications (1)

Publication Number Publication Date
PT2707391T true PT2707391T (pt) 2018-02-06

Family

ID=46046250

Family Applications (1)

Application Number Title Priority Date Filing Date
PT127197630T PT2707391T (pt) 2011-05-13 2012-05-11 Anticorpos contra her3

Country Status (8)

Country Link
US (1) US9346883B2 (pt)
EP (1) EP2707391B1 (pt)
DK (1) DK2707391T3 (pt)
ES (1) ES2657862T3 (pt)
NO (1) NO2707391T3 (pt)
PL (1) PL2707391T3 (pt)
PT (1) PT2707391T (pt)
WO (1) WO2012156309A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2013002046A (es) 2010-08-20 2013-04-03 Novartis Ag Anticuerpos para el receptor del factor de crecimiento epidermico 3 (her3).
KR20140099315A (ko) * 2011-12-05 2014-08-11 노파르티스 아게 Her3의 도메인 iii 및 도메인 iv에 대해 지시된 표피 성장 인자 수용체 3 (her3)에 대한 항체
SG11201607109QA (en) 2014-02-28 2016-09-29 Merus Nv Antibodies that bind egfr and erbb3
SI3110849T1 (sl) * 2014-02-28 2021-01-29 Merus N.V. Protitelo, ki veže ERBB-2 in ERBB-3
PL3365373T3 (pl) 2015-10-23 2021-08-23 Merus N.V. Molekuły wiążące, które hamują wzrost nowotworu
CN110650752A (zh) 2017-03-31 2020-01-03 美勒斯公司 用于治疗具有NRG1融合基因的细胞的ErbB-2和ErbB3结合双特异性抗体
CA3064333A1 (en) * 2017-05-29 2018-12-06 Gamamabs Pharma Cancer-associated immunosuppression inhibitor
BR112020002695A2 (pt) 2017-08-09 2020-08-25 Merus N.V. anticorpos que se ligam à egfr e cmet

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4861719A (en) 1986-04-25 1989-08-29 Fred Hutchinson Cancer Research Center DNA constructs for retrovirus packaging cell lines
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
GB8725529D0 (en) 1987-10-30 1987-12-02 Delta Biotechnology Ltd Polypeptides
US5278056A (en) 1988-02-05 1994-01-11 The Trustees Of Columbia University In The City Of New York Retroviral packaging cell lines and process of using same
CA2006596C (en) 1988-12-22 2000-09-05 Rika Ishikawa Chemically-modified g-csf
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
US5670488A (en) 1992-12-03 1997-09-23 Genzyme Corporation Adenovirus vector for gene therapy
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
EP0640094A1 (en) 1992-04-24 1995-03-01 The Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
CA2156725A1 (en) 1993-02-22 1994-09-01 Warren S. Pear Production of high titer helper-free retroviruses by transient transfection
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
FR2712812B1 (fr) 1993-11-23 1996-02-09 Centre Nat Rech Scient Composition pour la production de produits thérapeutiques in vivo.
IL116816A (en) 1995-01-20 2003-05-29 Rhone Poulenc Rorer Sa Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
KR101155191B1 (ko) 1999-01-15 2012-06-13 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
ES2571230T3 (es) 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
DK1522590T3 (da) 2000-06-28 2009-12-21 Glycofi Inc Fremgangsmåde til fremstilling af modificerede glykoproteiner
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
AR056857A1 (es) * 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
DK2129396T3 (da) 2007-02-16 2013-11-25 Merrimack Pharmaceuticals Inc Antistoffer mod ErbB3 og anvendelser deraf
EP2233500A1 (en) 2009-03-20 2010-09-29 LFB Biotechnologies Optimized Fc variants

Also Published As

Publication number Publication date
US9346883B2 (en) 2016-05-24
ES2657862T3 (es) 2018-03-07
NO2707391T3 (pt) 2018-04-07
WO2012156309A1 (en) 2012-11-22
PL2707391T3 (pl) 2018-04-30
EP2707391B1 (en) 2017-11-08
US20140141019A1 (en) 2014-05-22
EP2707391A1 (en) 2014-03-19
DK2707391T3 (en) 2018-02-05

Similar Documents

Publication Publication Date Title
HUS2400016I1 (hu) FCRN elleni antitestek
HRP20180640T1 (hr) Anti-b7-h3 antitijelo
IL259826A (en) Anti-alphabetatisiar antibody
IL264558A (en) Anti–il–23p19 antibodies
GB201103955D0 (en) Antibodies
GB201112056D0 (en) Antibodies
HK1204571A1 (en) Protease-regulated antibodies
HK1210192A1 (en) Anti-siglec-15 antibodies siglec-15
EP2788377A4 (en) HER3 ANTIBODIES AND USES THEREOF
EP2722343A4 (en) ANTI-ERBB3 ANTIBODIES
PT2707391T (pt) Anticorpos contra her3
TWI563004B (en) Anti-hxcr1 antibody
HK1210186A1 (en) Anti-h7cr antibodies h7cr
HK1200852A1 (en) New antibodies against phosphorylcholine
EP2714074A4 (en) ANTIBODIES AGAINST EMR1
EP2769988A4 (en) ANTI-GAP43 ANTIBODY
GB201116342D0 (en) Antigen combinations